Terms: = Brain cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Prognosis
609 results:
1. Targeting inflammation in glioblastoma: An updated review from pathophysiology to novel therapeutic approaches.
Alorfi NM; Ashour AM; Alharbi AS; Alshehri FS
Medicine (Baltimore); 2024 May; 103(21):e38245. PubMed ID: 38788009
[TBL] [Abstract] [Full Text] [Related]
2. mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.
Azimi P; Yazdanian T; Ahmadiani A
BMC Cancer; 2024 May; 24(1):612. PubMed ID: 38773447
[TBL] [Abstract] [Full Text] [Related]
3. CDCA3 is a potential biomarker for glioma malignancy and targeted therapy.
Han C; Liu S; Ji Y; Hu Y; Zhang J
Medicine (Baltimore); 2024 May; 103(19):e38066. PubMed ID: 38728485
[TBL] [Abstract] [Full Text] [Related]
4. Antioxidant network-based signatures cluster glioblastoma into distinct redox-resistant phenotypes.
Yang Y; More S; De Smet F; De Vleeschouwer S; Agostinis P
Front Immunol; 2024; 15():1342977. PubMed ID: 38698847
[TBL] [Abstract] [Full Text] [Related]
5. Multi-Omics Pan-cancer Analysis of Procollagen N-Propeptidase Gene Family of ADAMTS as Novel Biomarkers to Associate with prognosis, Tumor Immune Microenvironment, Signaling Pathways, and Drug Sensitivities.
Chen Y; Xiao C; Fan Q; Zhang Y; Huang Q; Ou Y
Front Biosci (Landmark Ed); 2024 Apr; 29(4):151. PubMed ID: 38682182
[TBL] [Abstract] [Full Text] [Related]
6. A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.
Du Z; Jiang Y; Yang Y; Kang X; Yan J; Liu B; Yang M
Sci Rep; 2024 Apr; 14(1):9427. PubMed ID: 38658591
[TBL] [Abstract] [Full Text] [Related]
7. Diffusion- and Perfusion-Weighted MRI Radiomics for Survival Prediction in Patients with Lower-Grade Gliomas.
Park CJ; Kim S; Han K; Ahn SS; Kim D; Park YW; Chang JH; Kim SH; Lee SK
Yonsei Med J; 2024 May; 65(5):283-292. PubMed ID: 38653567
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of the sodium pump subunit ATP1A3 in glioma patients: Potential value in prognostic prediction and immunotherapy.
Lan YL; Zou S; Qin B; Zhu X
Int Immunopharmacol; 2024 May; 133():112045. PubMed ID: 38615384
[TBL] [Abstract] [Full Text] [Related]
9. Development and validation of a multi-modality fusion deep learning model for differentiating glioblastoma from solitary brain metastases.
Shen S; Li C; Fan Y; Lu S; Yan Z; Liu H; Zhou H; Zhang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Jan; 49(1):58-67. PubMed ID: 38615167
[TBL] [Abstract] [Full Text] [Related]
10. Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines.
Marallano VJ; Ughetta ME; Tejero R; Nanda S; Ramalingam R; Stalbow L; Sattiraju A; Huang Y; Ramakrishnan A; Shen L; Wojcinski A; Kesari S; Zou H; Tsankov AM; Friedel RH
Sci Rep; 2024 Mar; 14(1):7246. PubMed ID: 38538643
[TBL] [Abstract] [Full Text] [Related]
11. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
[TBL] [Abstract] [Full Text] [Related]
12. Computational Fractal-Based Analysis of brain Tumor Microvascular Networks.
Di Ieva A; Al-Kadi OS
Adv Neurobiol; 2024; 36():525-544. PubMed ID: 38468051
[TBL] [Abstract] [Full Text] [Related]
13. Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.
Lofiego MF; Piazzini F; Caruso FP; Marzani F; Solmonese L; Bello E; Celesti F; Costa MC; Noviello T; Mortarini R; Anichini A; Ceccarelli M; Coral S; Di Giacomo AM; Maio M; Covre A;
J Transl Med; 2024 Mar; 22(1):223. PubMed ID: 38429759
[TBL] [Abstract] [Full Text] [Related]
14. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W; Liu Z; Liu T
Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
[TBL] [Abstract] [Full Text] [Related]
15. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Shirai Y; Ueno T; Kojima S; Ikeuchi H; Kitada R; Koyama T; Takahashi F; Takahashi K; Ichimura K; Yoshida A; Sugino H; Mano H; Narita Y; Takahashi M; Kohsaka S
J Neurooncol; 2024 Mar; 167(1):75-88. PubMed ID: 38363490
[TBL] [Abstract] [Full Text] [Related]
16. The Significance of the Redox Gene in the prognosis and Therapeutic Response of Glioma.
Niu H; Cao H; Liu X; Chen Y; Cheng Z; Long J; Li F; Sun C; Zuo P
Am J Clin Oncol; 2024 Jun; 47(6):259-270. PubMed ID: 38318849
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion.
Yu W; Zhou M; Niu H; Li J; Li Q; Xu X; Liang F; Rui C
BMC Cancer; 2024 Jan; 24(1):140. PubMed ID: 38287266
[TBL] [Abstract] [Full Text] [Related]
18. Radiomic profiling for insular diffuse glioma stratification with distinct biologic pathway activities.
Duan W; Wang Z; Ma Z; Zheng H; Li Y; Pei D; Wang M; Qiu Y; Duan M; Yan D; Ji Y; Cheng J; Liu X; Zhang Z; Yan J
Cancer Sci; 2024 Apr; 115(4):1261-1272. PubMed ID: 38279197
[TBL] [Abstract] [Full Text] [Related]
19. Immune-related lncRNAs signature and radiomics signature predict the prognosis and immune microenvironment of glioblastoma multiforme.
Luan J; Zhang D; Liu B; Yang A; Lv K; Hu P; Yu H; Shmuel A; Zhang C; Ma G
J Transl Med; 2024 Jan; 22(1):107. PubMed ID: 38279111
[TBL] [Abstract] [Full Text] [Related]
20. Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors.
Yan N; Xie W; Wang D; Fang Q; Guo J; Chen Y; Li X; Gong L; Wang J; Guo W; Zhang X; Zhang Y; Gu J; Li C
Genome Med; 2024 Jan; 16(1):2. PubMed ID: 38167466
[TBL] [Abstract] [Full Text] [Related]
[Next]
